Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 for chronic troublesome sialorrhea in children and adolescents with neurological disorders or intellectual disability
2013-004532-30Phase 3Completed
- Sponsor
- Merz
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in hypersalivation (3 arms), sponsored by Merz. Primary endpoints: Change in unstimulated salivary flow rate from baseline to Week 4 and Global Impression of Change Scale at Week 4. Started Oct 2014; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
hypersalivation
Beyond the preview
Go deeper on 2013-004532-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004532-30.